Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Recorded changes
83,427 on record
Recorded policy changes, newest first| Recorded | Payer | Policy | Change |
|---|
| Aug 2, 2026 | Independence Blue Cross | Outpatient Diabetes Education and Self-Management TrainingPayerPolicy · IBX-COMMERCIAL-12-05-01 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Otoplasty or Non-Surgical External Ear MoldingPayerPolicy · IBX-COMMERCIAL-11-01-01 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Ostomy SuppliesPayerPolicy · IBX-COMMERCIAL-05-00-50 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Osteogenic Stimulators (non-invasive, invasive/semi-invasive, electrical and ultrasound)PayerPolicy · IBX-COMMERCIAL-05-00-81 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Osteochondral Autograft Transplantation (Independence Administrators)PayerPolicy · IBX-COMMERCIAL-11-14-09 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Osteochondral Allograft Transplantation (Independence Administrators)PayerPolicy · IBX-COMMERCIAL-11-14-12 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Orthoptic/Pleoptic TrainingPayerPolicy · IBX-COMMERCIAL-07-13-01 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Orthognathic SurgeryPayerPolicy · IBX-COMMERCIAL-11-14-08 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Omalizumab (Xolair) and related biosimilarsPayerPolicy · IBX-COMMERCIAL-08-00-55 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | olipudase alfa-rpcp (Xenpozyme)PayerPolicy · IBX-COMMERCIAL-08-01-96 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Off-label Coverage for Prescription Drugs and/or BiologicsPayerPolicy · IBX-COMMERCIAL-08-00-15 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Octreotide Acetate (Sandostatin LAR Depot)PayerPolicy · IBX-COMMERCIAL-08-01-10 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Ocrelizumab (Ocrevus) and Ocrelizumab and Hyaluronidase-ocsq (Ocrevus Zunovo)PayerPolicy · IBX-COMMERCIAL-08-01-38 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Obstetrical Ultrasounds for Members Enrolled in a Health Maintenance Organization (HMO) or Health Maintenance Organization Point-of-Service (HMO-POS) ProductPayerPolicy · IBX-COMMERCIAL-00-03-10 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Nutritional Formulas, Enteral Nutrition, Medical Foods, Low-Protein Modified Food Products, and Donated Breast MilkPayerPolicy · IBX-COMMERCIAL-08-00-18 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | NucleoplastyPayerPolicy · IBX-COMMERCIAL-11-15-19 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Not Medically Necessary Services and Obsolete or Unreliable Diagnostic TestsPayerPolicy · IBX-COMMERCIAL-00-01-24 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Non-Surgical Spinal Decompression TherapyPayerPolicy · IBX-COMMERCIAL-07-08-01 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Noninvasive Techniques for the Evaluation and Monitoring of Individuals with Chronic Liver DiseasePayerPolicy · IBX-COMMERCIAL-06-02-56 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Noninvasive Respiratory Assist Devices (RADs): Continuous Positive Airway Pressure (CPAP) Devices, Auto-Adjusting Positive Airway Pressure (APAP) and Bi-Level DevicesPayerPolicy · IBX-COMMERCIAL-05-00-30 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Noninvasive Prenatal Screening for Fetal Aneuploidies Using Cell-Free Fetal DNA (Independence Administrators)PayerPolicy · IBX-COMMERCIAL-06-02-47 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Nonemergent Inpatient Video Electroencephalogram (EEG) Monitoring and Ambulatory EEG Monitoring in the HomePayerPolicy · IBX-COMMERCIAL-07-03-25 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Noncontraceptive Use of the Levonorgestrel-Releasing Intrauterine SystemPayerPolicy · IBX-COMMERCIAL-07-10-05 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Nogapendekin alfa inbakicept-pmln (Anktiva)PayerPolicy · IBX-COMMERCIAL-08-02-26 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Nivolumab and Relatlimab-rmbw (Opdualag) for intravenous usePayerPolicy · IBX-COMMERCIAL-08-01-94 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Nivolumab (Opdivo), Nivolumab and Hyaluronidase-nvhy (Opdivo Qvantig)PayerPolicy · IBX-COMMERCIAL-08-01-62 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Nipocalimab-aahu (Imaavy)PayerPolicy · IBX-COMMERCIAL-08-02-43 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Never Events and Preventable Serious Adverse EventsPayerPolicy · IBX-COMMERCIAL-00-01-44 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Neuropsychological Testing for Neurologically Based ConditionsPayerPolicy · IBX-COMMERCIAL-07-03-08 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Neuromuscular Electrical Stimulators (NMES) and Functional Electrical Stimulators (FES)PayerPolicy · IBX-COMMERCIAL-05-00-73 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Nerve Fiber Density TestingPayerPolicy · IBX-COMMERCIAL-06-02-38 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Negative Pressure Wound Therapy SystemsPayerPolicy · IBX-COMMERCIAL-05-00-38 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Nebulizers and Inhalation SolutionsPayerPolicy · IBX-COMMERCIAL-05-00-15 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Natalizumab (Tysabri) and Related BiosimilarsPayerPolicy · IBX-COMMERCIAL-08-00-64 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Nadofaragene Firadenovec-vncg (Adstiladrin)PayerPolicy · IBX-COMMERCIAL-08-02-11 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Musculoskeletal Services (Independence)PayerPolicy · IBX-COMMERCIAL-00-01-66 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Multiple Surgery Payment ReductionPayerPolicy · IBX-COMMERCIAL-11-00-10 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Multiple Procedure Payment Reduction Guidelines for Physical, Occupational, and Speech Therapy ServicesPayerPolicy · IBX-COMMERCIAL-00-01-68 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Multiple Procedure Payment Reduction (MPPR) on Certain Diagnostic ServicesPayerPolicy · IBX-COMMERCIAL-00-01-60 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Multiple Procedure Payment Reduction (MPPR) Guidelines for Transvaginal and Transabdominal UltrasoundsPayerPolicy · IBX-COMMERCIAL-00-01-72 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Multigene Expression Assays for Predicting Recurrence in Colon Cancer (Independence Administrators)PayerPolicy · IBX-COMMERCIAL-06-02-32 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Mosunetuzumab-axgb (Lunsumio)PayerPolicy · IBX-COMMERCIAL-08-02-00 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's DiseasePayerPolicy · IBX-COMMERCIAL-08-01-93 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Molecular Testing for the Management of Pancreatic Cysts or Barrett's Esophagus (Independence Administrators)PayerPolicy · IBX-COMMERCIAL-06-02-36 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Mohs Micrographic Surgery (MMS)PayerPolicy · IBX-COMMERCIAL-11-08-23 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Mogamulizumab-kpkc (Poteligeo)PayerPolicy · IBX-COMMERCIAL-08-01-52 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Modifiers XE, XP, XS, XU, and 59PayerPolicy · IBX-COMMERCIAL-03-00-08 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Modifiers for Split or Shared Surgical Services (Modifiers 54, 55, and 56)PayerPolicy · IBX-COMMERCIAL-03-00-31 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Modifiers for Assistant-at-Surgery Services: 80, 81, 82, and ASPayerPolicy · IBX-COMMERCIAL-00-10-18 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Modifiers 26 (Professional Component) and TC (Technical Component)PayerPolicy · IBX-COMMERCIAL-03-00-20 | New policy |
|---|